Most TMS clinics treat depression with a single fixed protocol applied to a single fixed target. That's how it got FDA-approved. But the brain is not a single target — and the same machine, programmed differently, can do much more.
Transcranial magnetic stimulation (TMS) uses a focused magnetic pulse to excite or inhibit cortical activity in a specific region. In its FDA-approved psychiatric form, TMS is delivered to the left dorsolateral prefrontal cortex at fixed frequencies, in fixed doses, across roughly thirty sessions. It is genuinely effective for treatment-resistant depression — that's why insurers cover it.
The same hardware, supervised by the right physician and pointed at the right network, can address attention, executive function, sleep architecture, anxiety, post-concussion symptoms and cognitive performance. The variable is not the machine. The variable is what comes before the machine.
What qEEG actually measures
A quantitative EEG (qEEG) is a high-resolution map of your brain's electrical activity at rest and under cognitive load. Surface electrodes capture millisecond-by-millisecond voltage shifts across nineteen standard sites; software then decomposes those signals into five frequency bands and compares your pattern to a normative database matched to your age and sex.
The output isn't a single score. It's a brain-wide deviation map: which networks are over- or under-active, which bands are dysregulated, and where the connectivity between regions has drifted from the population baseline. That map is the prescription pad. Without it, TMS becomes educated guessing.
Why "general" TMS leaves performance on the table
The FDA-cleared depression protocol assumes a homogeneous patient — one whose pathology lives in a known location, in a known band, at a known direction. Most longevity-medicine candidates are not that patient. The cognitive complaint they bring isn't depression. It's brain fog, executive slowdown, sleep fragmentation, a post-concussion lag, or a subtle decline they can feel before any standard test catches it.
Pointing a generic protocol at that complaint may help. It may also miss. qEEG-guided TMS replaces "may" with a defensible target.
Brain map first. Prescribe second. Stimulate third.
How a BioHaus qEEG-guided arc runs
- Week 0 — BaselineqEEG acquisition and physician read
60-minute resting and task-state EEG across 19 sites. Dr. Khoury reviews the spectral, coherence, and z-score maps and identifies the network targets — typically two to three regions, with band-specific direction (excite vs. inhibit).
- Weeks 1–6 — Active arcTargeted TMS sessions
Three to five sessions per week, dose-matched to your map. Frequencies and intensities are tuned per region rather than fixed, and protocols are adjusted at the midpoint based on subjective response and any safety thresholds.
- Week 6 — Mid-arc checkCognitive testing & symptom panel
Standardized cognitive battery (attention, processing speed, working memory) plus structured symptom panels. Adjustments are made before the second half if any target is under-responding.
- Week 12 — Re-baselineRepeat qEEG + outcomes review
Full qEEG repeat, head-to-head with baseline. Outcomes are quantified network-by-network. Maintenance frequency is set based on response durability — typically a single session every 4–6 weeks.
Who qEEG-guided TMS is for — and isn't
The members who get the most out of this arc are the ones who can articulate a specific cognitive complaint — measurable, repeatable, frustrating — that hasn't responded to sleep, training, supplements, and the obvious lifestyle work. Post-concussion patients. High performers with attention slippage. People recovering from a long cognitive insult.
It is not a productivity hack. We screen out anyone for whom standard psychiatric care should come first, anyone with active seizure history, certain implants, or pregnancy. The clinical bar is the bar.
If you're curious whether your brain has the kind of map that would benefit, the honest answer is: nobody knows until the map is taken. That's the point.
